Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Vitamin-mediated Cell Delivery of Oligonucleotides – an Attractive Approach for Therapeutic Applications

Published: Wednesday, May 21, 2014
Last Updated: Thursday, May 22, 2014
Bookmark and Share
Link Technologies Ltd has announced the availability of a novel vitamin modifier, which has shown in initial tests to have the potential of improving cell delivery of oligonucleotides.

The new reagent, 5’-Niacin-CE Phosphoramidite, is easily incorporated during solid phase oligo synthesis. The niacin-based modifier from Link offers several advantages over the use of conventional lipophilic delivery agents, including reduced risk of in vivo toxicity, and removes the necessity of cleaving the delivery reagent once in the cell. These benefits make vitamins, including niacin, an attractive method for the delivery of therapeutic oligonucleotides, such as siRNA, into cells.

While lipophilic modifier reagents have been shown to enhance cell penetration, vitamin-mediated cell delivery offers a distinct advantage due to the fact that vitamins are required, but not produced by cells. As such, it is believed that interaction with a specific binding protein is required before the vitamin-oligo conjugate is internalised. Not only does this enhance delivery and overcome the risk of toxicity, as the vitamin-based reagents are recognised by the cell, but it also offers some exciting potential for cell targeting.

Derived from niacin, an essential vitamin heavily involved in the biosynthesis of NAD and NADH, Link’s new vitamin modifier, 5’-Niacin-CE Phosphoramidite, is significantly less hydrophobic and less bulky than existing delivery agents. Whereas large lipophilic modifiers can supress an oligo’s function in vivo and therefore require cleaving, which is difficult to control, it is expected that with vitamin-based modifiers, intracellular cleavage of modifiers is not necessary. Potentially, this will lead to a reduction in required dosage of the therapeutic oligonucleotide, importantly minimising the risk of drug toxicity and side effects to the patient.

Catherine McKeen, Head of Technology Commercialisation, explained: “The ability to incorporate vitamin modifiers during oligo synthesis opens up significant potential to utilise a range of vitamin-oligonucleotide conjugates as a means of enhanced cellular uptake of therapeutic oligonucleotides.  5’-Niacin-CE Phosphoramidite is the second vitamin-based reagent in Link’s portfolio, alongside our tocopherol modifiers, and we will continue to add to this range.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
RNA-Based Drugs Give More Control Over Gene Editing
CRISPR/Cas9 gene editing technique can be transiently activated and inactivated using RNA-based drugs, giving researchers more precise control in correcting and inactivating genes.
University of Glasgow Researchers Make An Impact in 60 Seconds
Early-career researchers were invited to submit an engaging, dynamic and compelling 60 second video illuminating an aspect of their research.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
Dead Bacteria to Kill Colorectal Cancer
Scientists from Nanyang Technological University (NTU Singapore) have successfully used dead bacteria to kill colorectal cancer cells.
CRISPR-Cas9 Gene Editing: Check Three Times, Cut Once
Two new studies from UC Berkeley should give scientists who use CRISPR-Cas9 for genome engineering greater confidence that they won’t inadvertently edit the wrong DNA.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos